SSII

SS Innovations International (SSII) has seen its stock decline 31.8% over three months amid widening losses, mounting operating expenses, and cash burn concerns. While the company benefits from growing adoption of its robotic surgery systems and expanding global presence, persistent profitability challenges, liquidity constraints, and heavy geographic concentration in India (93% of revenues) remain significant headwinds. The company trades at a premium valuation of 8.64X EV/sales compared to the industry average of 2.78X.

The article profiles two rare microcap companies generating majority sales outside the US: SS Innovations International (SSII), a surgical robotics company with 87% of sales from India showing strong 39.4% YOY revenue growth but facing cash burn issues, and Iveda Solutions (IVDA), an AI-driven smart city technology provider with 91% of sales from Taiwan that generates lumpy, project-driven revenue from government contracts.

Zacks Investment Research initiated coverage of SS Innovations International (SSII) with a Neutral recommendation. The surgical robotics company shows strong growth in system installations (up 42% to 238 units) and procedure volumes (up 79% to 14,103), with revenues increasing to $25 million in H1 2026. However, persistent operating losses of $6.2 million, financing needs, regulatory uncertainties, and competition from established manufacturers temper the outlook.